rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ABOS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Acumen Pharmaceuticals Stock: ALTITUDE-AD Failure Destroys The Investment Thesis (ABOS)

      Acumen Pharmaceuticals' lead Alzheimer's drug sabirnetug failed to show clinical efficacy in the ALTITUDE-AD trial. See why ABOS stock is downgraded to a sell.

      Oct 31Seeking AlphaABOS
      Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

      CRYSTAL LAKE, Ill., September 14, 2026--Aptar and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

      Sep 14Yahoo FinanceABOSATR
      AptarGroup, Mass General Partner on Nose-to-Brain Drug Delivery Research
      Sep 14Yahoo FinanceABOS

      This is the newest page. Registered accounts read further back.